Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group

Volumn 27, Issue 2, 2011, Pages 107-117

  Lesyk, R B ^a   Zimenkovsky, B S ^a   Kaminskyy, D V ^a   Kryshchyshyn, A P ^a   Havryluk, D Ya ^a   Atamanyuk, D V ^a   Subtel’na, I Yu ^a   Khyluk, D V ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

(Q)SAR; 3 d thiazoles; 4 thia(imida)zolidinones; Anticancer activity; Synthesis; Thiopyrano 2

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; HETEROCYCLIC COMPOUND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER MODEL; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; MOLECULAR DOCKING; OVARY CANCER; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

THIA;

EID: 79957671997     PISSN: None     EISSN: None     Source Type: None    
DOI: 10.7124/bc.000089     Document Type: Article

References (49)

1. Lesyk R. B., Zimenkovsky B. S. 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr. Org. Chem. 2004. 8, N 16. P. 1547-1577.
2. Prabhakar Y. S., Solomon V. R., Gupta M. K., Katti S. B. QSAR studies on thiazolidines: a biologically privileged scaffold. Top. Heterocycl. Chem. 2006. 4. P. 161-249.
3. Tomasic T., Masic L. P. Rhodanine as a privileged scaffold in drug discovery. Curr. Med. Chem. 2009.16, N 13. P. 1596-1629.
4. Reginato M. J., Bailey S. T., Krakow S. L., Minami C., Ishii S., Tanaka H., Lazar M. A. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gammaactivating properties. J. Biol. Chem. 1998. 273, N 49. P. 32679-32684.
5. Kador P. F., Kinoshita J. H., Sharpless N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem. 1985. 28, N 7. P. 841-849.
6. Charlier C., Mishaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003. 38, N 7 8. P. 645-659.
7. The Merck Index.Eds M. J. O'Neil et al.:13th ed.-New Jersey, 2001. 1818 p.
8. Sim M. M., Ng S. B., Buss A. D., Crasta S. C., Goh K. L., Lee S. K. Benzylidene rhodanines as novel inhibitors of UDP-N-ace-tylmuramate/L-alanine ligase. Bioorg. Med. Chem. Lett. 2002. 12, N 4.P. 697-699.
9. Theocharisa S., Margeli A., Kouraklis G. Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr. Med. Chem. Anticancer Agents. 2003. 3, N 3. P. 239-251.
10. Murphy G. J., Holder J. C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 2000. 21, N 12. P. 469-474.
11. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 2001. 3, N 2. P. 173-182.
12. Carter P. H., Scherle P. A., Muckelbauer J. K., Voss M. E., Liu R.-Q., Thompson L. A., Tebben A. J., Solomon K. A., Lo Y. C., Li Z., Strzemienski P., Yang G., Falahatpisheh N., Xu M., Wu Z., Farrow N. A., Ramnarayan K., Wang J., Rideout D., Yalamoori V., Domaille P., Underwood D. J., Trzaskos J. M., Friedman S. M., Newton R. C., Decicco C. P. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc. Natl Acad. Sci. USA. 2001. 98, N 21. P. 11879-11884.
13. Zheng W., Degterev A., Hsu E., Yuan J., Yuan C. Structure-activity relationship study of a novel necroptosis inhibitor, necro-statin-7. Bioorg. Med. Chem. Lett. 2008. 18, N 18. P. 4932-4935.
14. Dayam R., Aiello F., Deng J., Wu Y., Garofalo A., Chen X., Nea- mati N. Discovery of small molecule integrin avb3 antagonists as novel anticancer agents. J. Med. Chem. 2006. 49, N 15. P. 4526-4534.
15. Cutshall N. S., O’Day C., Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg. Med. Chem. Lett. 2005. 15, N 14. P. 3374-3379.
16. Xia Z., Knaak C., Ma J., Beharry Z. M., McInnes C., Wang W., Kraft A. S., Smith C. D. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 2009. 52, N 1. P. 74-86.
17. Ottana R., Maccari R., Barreca M. L., Bruno G., Rotondo A., Rossi A., Chiricosta G., Di Paola R., Sautebin L., Cuzzocrea S., Vigorita M. G. 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents. Bioorg. Med. Chem. 2005. 13, N 13. P. 4243-4252.
18. Lesyk R., Zimenkovsky B., Kaminskyy D., Holota S., Atamanyuk D., Havryluk D., Nektegayev I., Kazmirchuk G., Subtel’na I., Roman O., Kryshchyshyn A., Khyluk D. Anticancer potential of 4-azolidones and related heterocycles. Annal. UMCS. Sectio DDD. 2006. 19, N 1. P. 107-110.
19. Lesyk R., Vladzimirska O., Zimenkovsky B., Horishny V., Nektegayev I., Solyanyk V., Vovk O. New thiazolidones-4 with pyrazolone-5 substituent as the potential NSAIDs. Bol. Chim. Farm. 1998. 137, N 6. P. 210-217.
20. Lesyk R. B., Artemenko A. G., Zimenkovsky B. S., Kuz’min V. E., Nektegayev I. O., Roman O. M., Atamanyuk D. V. Pharmaco logical screening and 2D-QSAR analysis of anti-inflammatory activity of 4-thiazolidone derivatives. Farmacevtychnyj Zhur. 2003. N 3. P. 58-61.
21. Lesyk R., Zimenkovsky B., Subtelna I., Nektegayev I., Kazmirchuk G. Synthesis and antinflammatory activity of some 2-aryl-amino-2-thiazoline-4-ones. Acta Pol. Pharm. 2003. 60, N 6. P. 457-466.
22. Lesyk R., Zimenkovsky B., Kutsyk R. V., Atamanyuk D. V., Semenciv G. M. Synthesis and studing of antimicrobial activity of azolidine derivatives with 2-(2-chlorobenzyloxy)-5-nitrophenyl fragment in molecules. Farmacevtychnyj Zhur. 2003. N 2. P. 52-56.
23. Zimenkovskii B. S., Kutsyk R. V., Lesyk R. B., Matyichuk V. S., Obushak N. D., Klyufinska T. I. Synthesis and antimicrobial activity of 2,4-dioxothiazolidine-5-acetic acid amides. Pharm. Chem. J. 2006. 40, N 6. P. 303-306.
24. Nektegayev I., Lesyk R. 3-Oxyarylthiazolidones-4 and their choleretic activity. Sci. Pharm. 1999. 67. P. 227-230.
25. Lukyanchuk V. D., Zimenkovsky B. S., Lesyk R. B., Nemyatykh O. D., Nektegayev I. O. Antioxidant activity of 5-arylidene-2,4-thazolidinedione-3-alkanoic acid derivatives. J. Pharm. Pharmacol. 2002. 54, Suppl. S. 1.
26. Boyd M. R., Paull K. D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995. 34, N 2. P. 91-109.
27. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988. 48, N 3. P. 589-601.
28. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer. Inst. 1991. 83, N 11. P. 757-766.
29. Boyd M. R. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Cancer drug discovery and development/Ed. A. Teicher.-New Jersey: Humana press, 1997. Ch. 2. P. 23-43.
30. Shoemaker R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer. 2006. 6, N 10. P. 813-823.
31. Lesyk R., Zimenkovsky B., Atamanyuk D., Jensen F., Kiec-Kononowicz K., Gzella A. Anticancer thiopyrano[2,3-d][1,3]thiazol-2-ones with norbornane moiety. Synthesis, cytotoxicity, physico-chemical properties, and computational studies. Bioorg. Med. Chem. 2006. 14, N 15. P. 5230-5240.
32. Lesyk R., Vladzimirska O., Holota S., Zaprutko L., Gzella A. New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: synthesis and anticancer evaluation. Eur. J. Med. Chem. 2007. 42, N 5. P. 641-648.
33. Atamanyuk D., Zimenkovsky B., Lesyk R. Synthesis and anti-cancer activity of novel thiopyrano[2,3-d]thiazole-based compounds containing norbornane moiety. J. Sulf. Chem. 2008. 29, N 2. P. 151-162.
34. Matiychuk V. S., Lesyk R. B., Obushak M. D., Gzella A., Atamanyuk D. V., Ostapiuk Y. V., Kryshchyshyn A. P. A new domino-Knoevenagel-hetero-Diels-Alder reaction. Tetrahedron Lett. 2008. 49, N 31. P. 4648-4651.
35. Havrylyuk D., Zimenkovsky B., Vasylenko O., Zaprutko L., Gzella A., Lesyk R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem. 2009. 44, N 4. Р. 1396-1404.
36. Kaminskyy D., Zimenkovsky B., Lesyk R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur. J. Med. Chem. 2009. 44, N 9. Р. 3627-3636.
37. Mosula L., Zimenkovsky B., Havrylyuk D., Missir A.-V., Chirita I. C., Lesyk R. Synthesis and antitumor activity of novel 2-thioxo-4-thiazolidinones with benzothiazole moieties. Farmacia. 2009. 57, N 3. P. 321-330.
38. Havrylyuk D., Zimenkovsky B., Lesyk R. Synthesis and anticancer activity of novel nonfused bicyclic thiazolidinone derivatives. Phosphorus, Sulfur, and Silicon and the Related Elements. 2009. 184, N 3. Р. 638-650.
39. Subtel'na I., Atamanyuk D., Szymanska E., Kiec-Kononowicz K., Zimenkovsky B., Vasylenko O., Gzella A., Lesyk R. Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity. Bioorg. Med. Chem. 2010. 18, N 14. P. 5090-5102.
40. Havrylyuk D., Mosula L., Zimenkovsky B., Vasylenko O., Gzella A., Lesyk R. Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. Eur. J. Med. Chem. 2010. 45, N 11. P. 5012-5021.
41. Solomon V. R., Hu C., Lee H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg. Med. Chem. 2009. 17, N 21. P. 7585-7592.
42. Kaminskyy D. V., Lesyk R. B. Structure-anticancer activity relationships among 4-azolidinone-3-carboxylic acids derivatives. Biopolym. Cell. 2010. 26, N 2. P. 136-145.
43. Каminskyy D. V., Lesyk R. B. Synthesis and biological activity of 4-thiazolidinone-3-acetic acids derivatives. Farmacevtychnyj Zhur. 2008. N 3. P. 70-78.
44. Каminskyy D. V., Roman O. M., Atamanyuk D. V., Lesyk R. B. 5-Ylidene-2-thioxo-4-thiazolidinone-3-succinic acids and their derivatives: synthesis, anticancer activity, QSAR-analysis. J. Org. Pharm. Chem. 2006. 4, N 1 (13). P. 41-48.
45. Kryshchyshyn A. P., Zimenkovsky B. S., Zaprutko L., Lesyk R. B. Synthesis and antitumor activity evaluation of 3,5a,6,11b-tetrahydro-2H,5H-chromeno[4',3':4,5]thiopyrano[2,3-d]thiazole derivatives. J. Org. Pharm. Chem. 2010. 8, N 1 (29). P. 37-43.
46. Kryshchyshyn A., Zimenkovsky B., Lesyk R. Synthesis and anticancer activity in vitro of isothiochromеno[3,4-d]thiazole derivatives. Annal. UMCS. Sectio DDD. 2008. 21, N 1. P. 247-251.
47. Zaharevitz D. W., Holbeck S. L., Bowerman C., Svetlik P. A. COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. J. Mol. Graph. Model. 2002. 20, N 4. P. 297-303.
48. Paull K. D., Shoemaker R. H., Hodes L., Monks A., Scudiero D. A., Rubinstein L., Plowman J., Boyd M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst. 1989. 81, N 14. P. 1088-1092.
49. Brier S., Lemaire D., Debonis S., Forest E., Kozielski F. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry. 2004. 43, N 41. P. 13072-13082.